The global market for Macrolide Antibiotics is expected to grow at a significant CAGR during the forecast period (2021-2027). Antibiotics produced from Saccharopolyspora erythraea are known as macrolide antibiotics. Macrolide antibiotics are bacteriostatic, although they can be bactericidal at high bacterial concentrations. Erythromycin, clarithromycin, azithromycin, fidaxomicin, and telithromycin are the five kinds of macrolide antibiotics. These have anti-inflammatory and immunological modulatory properties and are used to treat a variety of ailments, including respiratory disorders, soft tissue infections, and sexually transmitted bacterial infections, among others.

Over the forecast period, the market is likely to be driven by pharmaceutical firms' increasing efforts to discover innovative treatments to treat infectious illnesses. According to the Pew Charitable Trust, in December 2019, about 41 promising compounds for the treatment of severe bacterial infections were being studied. Furthermore, favourable government legislation like the GAIN Act and the REVAMP Act is expected to speed up the clearance process throughout the world. Over the forecast period, the introduction of novel antibiotic drugs is likely to drive market growth.

Pharmaceutical firms are working on the development of novel medicines to lower the cost of medication development. For instance, in July 2019, Nosopharm announced a collaboration with Evotec AG to develop NOSO-502. It's a first-in-class novel antibiotics for infections caused by Enterobacteriaceae. Additionally, Forge Therapeutics, Inc. and Basilea Pharmaceutica Ltd. signed a research partnership and licencing agreement to develop new antibiotics in April 2019.

Furthermore, the growing number of public-private alliances in that the public agencies offer funds and novel R&D techniques to companies producing antibiotics is projected to increase the product pipeline. For instance, in March 2019, the Global Antibiotic Research and Development Collaboration (GARDP) and Evotec AG established a public-private partnership to create first-in-class antibiotics for treating drug-resistant bacterial illnesses.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered

o By Drugs 

o By Route of Administration 

o By Infection

o By End-User

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

• Competitive Landscape: GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., www.bpharmed.com, Zhejiang Guobang Pharmaceutical Co., Ltd. and Barkat Pharmaceutical Group among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Macrolide Antibiotics Market by Segments

By Drugs

• Azithromycin
• Clarithromycin
• Erythromycin
• Fidaxomicin
• Telithromycin

By Route of Administration

• Oral
• Parenteral

By Infection

• Mycoplasma pneumonia
• Legionella sp.
• Bordetella pertussis
• Symptomatic Cat-Scratch Disease
• Bacillary angiomatosis
• Peliosishepatis
• Cerebral Toxoplasmosis
• Uncomplicated Skin Infections

By End-User

• Hospital
• Dermatology Clinic
• Ambulatory Centre
• Research Laboratories

Global Macrolide Antibiotics Market by Region